Eli Lilly and Novo Nordisk shares rose Tuesday after the Biden administration proposed expanding coverage of the companies' ...

Shares of Danish weight-loss drug maker Novo Nordisk rose 1.3% on Tuesday as U.S. President Joe Biden proposed expanding ...

As far as competition goes, Eli Lilly is one of the two current leaders in the weight loss space, along with Novo Nordisk.

Investors were excited as U.S. President Joe Biden proposed expanding coverage of anti-obesity drugs for millions on Medicare ...

LLY's recent sell-off presents a buying opportunity for savvy investors, with strong growth potential in the GLP-1 market ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

Share of Amgen tumbled on Tuesday after the company's experimental weight-loss drug MariTide failed to meet lofty investor ...

Currently, Eli Lilly’s GLP-1 drugs Mounjaro and Zepbound (tirzepatide) are not on the FDA’s shortage list but compounded ...

Shares of Eli Lilly & Co. ($LLY) and Novo Nordisk A/S ($NVO) climbed in Tuesday’s premarket trading after the Biden ...